McCulley J P, Binder P S, Kaufman H E, O'Day D M, Poirier R H
Ophthalmology. 1982 Oct;89(10):1195-200. doi: 10.1016/s0161-6420(82)34668-0.
Thirty patients randomized to the Acyclovir (ACV) group (26 with dendritic lesions, 4 geographic lesions) and 34 patients randomized to the idoxuridine (IDU) treatment group (26 dendritic lesions, 8 geographic lesions) with epithelial herpetic keratitis were evaluated for efficacy and adverse reactions in a multi-center, double-masked, randomized, stratified trial. Patients were treated with either 3% acyclovir ophthalmic ointment or 0.5% idoxuridine ophthalmic ointment five times a day for 14 days. The results of the trial indicated no significant difference between ACV and IDU as antiviral agents in the treatment of epithelial herpetic keratitis. The overall healing patterns of ACV and IDU adjusted for lesion type and prognostic factors, including presenting condition (initial or recurrent disease), duration of symptoms, prior ophthalmic steroid use, and positive pretreatment herpesvirus culture, as well as, the healing patterns within each lesion type adjusted for these factors, were not significantly different between the two treatment groups. There was no significant difference between the two groups in the frequency of development of deeper involvement. The only significant difference (P less than 0.01) in the frequency of development of adverse reactions was found in the incidence of development of superficial punctate epitheliopathy (IDU-42%, ACV-11%).
30例被随机分配至阿昔洛韦（ACV）组（26例为树枝状病变，4例为地图状病变）和34例被随机分配至碘苷（IDU）治疗组（26例树枝状病变，8例地图状病变）的上皮性疱疹性角膜炎患者，在一项多中心、双盲、随机、分层试验中接受了疗效和不良反应评估。患者分别使用3%阿昔洛韦眼膏或0.5%碘苷眼膏，每日5次，共治疗14天。试验结果表明，在治疗上皮性疱疹性角膜炎方面，ACV和IDU作为抗病毒药物并无显著差异。根据病变类型和预后因素（包括就诊情况（初发性或复发性疾病）、症状持续时间、既往眼部类固醇使用情况以及治疗前疱疹病毒培养阳性）进行调整后，ACV和IDU的总体愈合模式，以及在对这些因素进行调整后每种病变类型内的愈合模式，在两个治疗组之间并无显著差异。两组在发生深层病变的频率上没有显著差异。在不良反应发生频率上唯一的显著差异（P小于0.01）在于浅层点状上皮病变的发生率（IDU组为42%，ACV组为11%）。
